Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyCharles J. Ryan, Dana E. Rathkopf, Ethan Basch et al.|New England Journal of Medicine|2012Cited by 2.8k
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyHoward I. Scher, Charles L. Sawyers, Tomasz M. Beer et al.|The Lancet|2010Cited by 1.1k
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate CancerKim N., Celio Kussumoto, Dana E. Rathkopf et al.|Journal of Clinical Oncology|2023Cited by 317
Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)Dana E. Rathkopf, Fred Saad, Matthew R. Smith et al.|European Urology|2014Cited by 273
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trialK.N. Chi, Eleni Efstathiou, Shahneen Sandhu et al.|Annals of Oncology|2023Cited by 195